PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,291 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total transaction of $58,533.94. Following the completion of the transaction, the chief accounting officer now owns 65,983 shares of the company’s stock, valued at approximately $2,991,669.22. This represents a 1.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Christine Marie Utter also recently made the following trade(s):

• On Monday, December 2nd, Christine Marie Utter sold 17,800 shares of PTC Therapeutics stock. The shares were sold at an average price of $51.77, for a total transaction of $921,506.00.

PTC Therapeutics Stock Down 2.4 %

PTC Therapeutics stock opened at $43.94 on Friday. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of -7.40 and a beta of 0.62. PTC Therapeutics, Inc. has a 12-month low of $23.58 and a 12-month high of $54.16. The business’s 50-day simple moving average is $45.19 and its 200 day simple moving average is $38.44.

Analyst Upgrades and Downgrades

Several research firms recently commented on PTCT. StockNews.com lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $64.00 target price on shares of PTC Therapeutics in a report on Tuesday, September 17th. Raymond James began coverage on shares of PTC Therapeutics in a report on Thursday, October 10th. They set a “market perform” rating for the company. UBS Group upped their price objective on shares of PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Finally, Morgan Stanley upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $45.00 to $67.00 in a research report on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, PTC Therapeutics presently has an average rating of “Hold” and an average target price of $54.08.

Institutional Investors Weigh In On PTC Therapeutics

Several institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its holdings in PTC Therapeutics by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 116,396 shares of the biopharmaceutical company’s stock worth $3,559,000 after acquiring an additional 7,314 shares during the period. Arizona State Retirement System grew its stake in shares of PTC Therapeutics by 3.4% during the second quarter. Arizona State Retirement System now owns 19,301 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 636 shares during the period. Quest Partners LLC bought a new stake in PTC Therapeutics in the second quarter valued at about $128,000. Choreo LLC lifted its stake in PTC Therapeutics by 4.1% in the second quarter. Choreo LLC now owns 11,426 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 452 shares during the period. Finally, Headlands Technologies LLC boosted its holdings in PTC Therapeutics by 83.2% during the second quarter. Headlands Technologies LLC now owns 6,611 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 3,002 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.